MilliporeSigma has bought the rights to the ProcessPad platform from Simplyfeye Softwares, adding the latest “building block” to its BioContinuum Platform.
The ProcessPad platform from Simplyfeye Softwares Private Limited brings MilliporeSigma a data management and analytics solution capable of capturing development, scale-up, commercial and process data on a single platform as well as analyzing quantitative and qualitative batch manufacturing data.
Financial details around the acquisition were not disclosed, but Michael Felo, director of Integrated Solutions Marketing, BioContinuum Platform, at MilliporeSigma, told us the ProcessPad platform will be the latest tool in its process intensification offering, BioContinuum.
â€śWith the acquisition of the ProcessPad technology, we complete another building block of our BioContinuum Platform journey, as we look to the control and orchestration of the entire platform,â€ť he said.
â€śProcessPad technology allows us to provide on-demand access to process and facility data with a web-based platform that enables straightforward aggregation, visualization, and analysis.â€ť
The firmâ€™s BioContinuum platform was launched last year and comprises of next-generation technologies aimed at obtaining incremental process benefits â€“ with a mind to continuous processing â€“ in the future.
â€śIt focuses on innovations in process intensification, process analytics, software and automation and single-use technologies and leverages a building block approach,â€ť said Felo, and the addition of the data management and analytics solution comes months after MilliporeSigma bolstered the platform through an integrated solution for buffer delivery.
â€śOur vision is to harness the power of the digital revolution, allowing mAb manufacturers to transform data into actions and accelerate the path of life saving therapeutics to patients.
â€śThrough the creation of a connected and intelligent digital ecosystem of software, systems and consumables for mAb manufacturers, we enable the automation of process execution and workflows to reduce risk, improve quality and accelerate time to market.â€ť
The BioContinuum platform plays into the shifting dynamics in the bioprocessing space as industry looks to more automated and intense technologies.
â€śIndustry 4.0 is poised to transform the production process and how facilities are run. The implications for bioprocessing are significant. Bioprocessing 4.0 will not rely on one specific technology or optimized process, but will be a collection of interconnected solutions bringing innovation across entire the ecosystem of equipment, operators and consumables,â€ť said Felo.
â€śIt will truly represent the seamless physical and digital integration of processing steps; bringing together the raw materials, production systems, consumables, testing and analytics that deliver streamlined and intensified biopharmaceutical manufacturing. ProcessPad technology offers transparency to all manufacturing data, connecting databases, historians, and other tools to enable smarter and faster analyses and decisionmaking.â€ť